Tanshinone IIA reverses gefitinib resistance in EGFR-mutant lung cancer via inhibition of SREBP1-mediated lipogenesis.
Lei ZhangChuncao XuJunyuan HuangShiqin JiangZhiyan QinLin CaoGuoyao TanZhongxiang ZhaoMin HuangJing JinPublished in: Phytotherapy research : PTR (2024)
Tan IIA improved gefitinib sensitivity via SREBP1-mediated lipogenesis. Tan IIA could be a potential candidate to enhance sensitivity for gefitinib-resistant NSCLC patients.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- advanced non small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- brain metastases
- tyrosine kinase
- prognostic factors
- type diabetes
- high fat diet induced
- metabolic syndrome
- insulin resistance
- patient reported outcomes
- patient reported